Addex, Merck ink potential $700 million licensing deal

ZURICH, Switzerland Addex Pharmaceuticals is stating that it may receive more than $700 million from a licensing deal it made with Merck regarding its drug ADX63365, which is used to treat schizophrenia, Reuters reported.

The company will receive $22 million upfront from Merck for the drug, which also covers undisclosed indications for the drug and will then be eligible for up to $680 million in milestone payments.

Addex also announced that its lead compound, ADX10059 failed to meet its main target in a mid-stage Phase IIa clinical trial for acute anxiety. Development of ADX10059 for two other indications, gastroesophageal reflux disease and migraines, will continue as planned, according to the company.

Login or Register to post a comment.